Beckman Coulter seeks authorization for $4 antigen test
Beckman Coulter said it would file for an emergency use authorization for a SARS-CoV-2 antigen test that costs only $4.
Beckman Coulter said it would file for an emergency use authorization for a SARS-CoV-2 antigen test that costs only $4.
Danaher Corp. (NYSE:DHR) agreed to pay about $6.8 billion in cash for Beckman Coulter Inc. (NYSE:BEC), ending weeks of jockeying for the Brea, Calif.-based diagnostics player.
Some private equity firms have dropped out of the running for Brea, Calif.-based medical device and diagnostics maker Beckman Coulter Inc., while others have explored banding together for an acquisition.
Several private equity firms are weighing a buyout of medical device and diagnostics maker Beckman Coulter Inc. (NYSE:BEC), according to news reports. Blackstone Group LP (NYSE:BX), Apollo Global Management LLC and Kohlberg Kravis Roberts & Co (NYSE:KKR) are among a handful of investment firms interested in the Brea, Calif.-based company after news surfaced that it was looking at strategic options, including a sale, according to Reuters.